Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The parents of a seven-year-old boy who died in a clinical trial have spoken of their "indescribable" pain. Ender Nihat, from Essex, suffered organ failure after receiving chemotherapy during ...

Assessing Pain, Anxiety and Other Symptoms of Nursing Home Residents Unable to Speak for Themselves Mar. 12, 2025 — As many as half of nursing home residents are cognitively impaired and may be ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...